Skip to contentF
Fulcrum Therapeutics, Inc.
F
FULCFulcrum Therapeutics, Inc. Q2 2025 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2024 Net Income-$17.30M-$17.30MN/M vs Q2 2024 EPS Diluted-$0.28-$0.28N/M vs Q2 2024 Operating Income-$19,815,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$13,885,000N/M ended Jun 30, 2025 · filed Jul 29, 2025 · 29 d after period end